Biogen trial of ALS drug fails main goal, but company says data are encouraging
Biogen trial of ALS drug fails main goal, but company says data are encouraging
A late-stage trial of Biogen Inc’s experimental treatment for an inherited form of amyotrophic lateral sclerosis (ALS) failed to reach its main goal, but secondary measures and biomarkers showed favorable trends, the company said on Sunday. Read More